Emmaus Life Sciences Inc., a biotechnology company based in Torrance, has raised $12 million in debt securities, according to securities filing.
The developer of a breakthrough medicine for sickle cell disease raised $12 million from sales of convertible debt securities to 18 investors, according to a Nov. 1 filing with the U.S. Securities and Exchange Commission.
Emmaus’ Endari drug, developed at LA BioMed on the campus of Harbor-UCLA Medical Center, is the first new treatment for sickle cell disease released in 20 years for adults and the first-ever treatment for children. It went on sale in January.
The inherited blood disorder affects 100,000 people across the nation, many of them African-Americans.
Highlights of a phase 3 clinical trial for the L-glutamine oral powder is expected to be announced in early December at an American Society of Hematology meeting in San Diego.
Health business reporter Dana Bartholomew can be reached at email@example.com. Follow him on Twitter @_DanaBart.
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- Emmaus Life Sciences Raises $2.6 Million From Investors
- Torrance-Based Emmaus Life Sciences Groundbreaking Sickle Cell Drug Goes on Sale
- Emmaus Cuts Deal to Market its Sickle Cell Drug to U.S. Service Members
- New Sickle Cell Drug Goes to Market
- Emmaus Life to Go Public Via Merger
- Emmaus Life Sciences to Go Public Via Merger
- Emmaus Plans Reverse Merger, Nasdaq Listing
- L.A. Biotech’s Summer Sizzle